Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2015 | Results of ELOQUENT-2 trial for treatment multiple myeloma

Joseph Mikhael • 2 Jun 2015
ASCO 2015
Multiple Myeloma Antibodies Dexamethasone Elotuzumab Lenalidomide

Dr Joseph Mikhael discusses the results of ELOQUENT-2, a phase 3, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma.

More from Joseph Mikhael

Bridging the gap in myeloma care: ensuring access for all patients
1:55
Bridging the gap in myeloma care: ensuring access for all patients
Joseph Mikhael • 5 Sep 2025
Areas of consensus and controversy in the current and future management of R/R multiple myeloma
2:36
Areas of consensus and controversy in the current and future management of R/R multiple myeloma
Joseph Mikhael • 5 Sep 2025
The benefits of telehealth in promoting equity in blood cancer care
2:11
The benefits of telehealth in promoting equity in blood cancer care
Joseph Mikhael • 5 Sep 2025
The importance of shared decision-making & patient preferences in myeloma care
1:56
The importance of shared decision-making & patient preferences in myeloma care
Joseph Mikhael • 5 Sep 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Joseph Mikhael • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Joseph Mikhael • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Joseph Mikhael • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Joseph Mikhael • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals